Document is current
Any future updates will be listed below
-
Authors
Engel, Sinah
Halcour, Johannes
Ellwardt, Erik
Uphaus, Timo
Steffen, Falk
Zipp, Frauke
Bittner, Stefan
Luessi, Felix
-
Funding
Funding for this research was provided by:
German Research Council (CRC-TR-128, CRC-TR-128, CRC-TR-128, CRC-TR-128)
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- License Information
-
More Information
Article History
Received: 29 August 2022
Accepted: 17 December 2022
First Online: 11 January 2023
Declarations
:
: The study was approved by the local ethics committee (ethics committee of the Landesärztekammer Rhineland Palatinate, number 837.019.10). Written informed consent was obtained from all participants.
: Not applicable.
: SE, EE, JH and FS declare no competing interests. TU received grants from advanceCOR, grants from Else Kröner-Fresenius Stiftung (2018_EKMS.21), personal fees from Merck Serono, personal fees from Pfizer. FZ has recently received research grants and/or consultation funds from Biogen, Ministry of Education and Research (BMBF), Bristol-Meyers-Squibb, Celgene, German Research Foundation (DFG), Janssen, Max-Planck-Society (MPG), Merck Serono, Novartis, Progressive MS Alliance (PMSA), Roche, Sanofi Genzyme, and Sandoz. SB has received funding for travel expenses for attending meetings from Merck Serono and honoraria from Biogen Idec, Bristol Meyer Squibbs, Merck Serono, Novartis, Roche, Sanofi Genzyme and TEVA. His research is funded by Deutsche Forschungsgemeinschaft (DFG) and Hertie foundation. FL received consultancy fees from Roche and support with travel costs from Teva Pharma.
